Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Current Cancer Therapy Reviews
Title:Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Volume: 12 Issue: 1
Author(s): Bahar Bahrani, Hannah Liu, Elizabeth M Marchionne and Amor Khachemoune
Affiliation:
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Abstract: Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Export Options
About this article
Cite this article as:
Bahrani Bahar, Liu Hannah, Marchionne M Elizabeth and Khachemoune Amor, Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160714151154
DOI https://dx.doi.org/10.2174/1573394712666160714151154 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-Level Secretory Expression and Purification of Recombinant Human Interleukin 1 Beta in Pichia pastoris
Protein & Peptide Letters Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Effect of Environmental Contaminants on Mammalian Testis
Current Molecular Pharmacology Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine Formulation Development and Evaluation of Transdermal 5-Fluorouracil Ethosomal Formulation through 2<sup>5-2</sup> Fractional Factorial Design
Drug Delivery Letters Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets FOXO1: A Potential Target for Human Diseases
Current Drug Targets CYLD-Mediated Signaling and Diseases
Current Drug Targets Predicting Chemotherapy Sensitivity Profiles for Breast Cancer Cell Lines with and Without Stem Cell-Like Features
Current Signal Transduction Therapy Monitoring Nucleic Acids Using Molecular Beacons
Current Pharmaceutical Biotechnology Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Verbascoside Attenuates Rac-1 and HIF-1α Signaling Cascade in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design